USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer

Michaela Reissland; Oliver Hartmann; Saskia Tauch; Jeroen Bugter; Cristian Prieto-Garcia; Clemens Schulte; Sinah Loebbert; Daniel Solvie; Eliya Bitman-Lotan; Ashwin Narain; Anne-Claire Jacomin; Christina Schuelein-Voelk; Carmina T. Fuss; Nikolett Pahor; Carsten Ade; Viktoria Buck; Michael Potente; Vivian Li; Gerti Beliu; Armin Wiegering; T.N. Grossmann; Martin Eilers; Elmar Wolf; Hans Michael Maric; Mathias T. Rosenfeldt; Madelon Maurice; Ivan Dikic; Peter Gallant; Amir Orian (Oryan); Markus E. Diefenbacher

doi:10.1038/s41388-024-03141-x

USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer

Michaela Reissland
, Oliver Hartmann
, Saskia Tauch
, Jeroen Bugter
, Cristian Prieto-Garcia
, Clemens Schulte
, Sinah Loebbert
, Daniel Solvie
, Eliya Bitman-Lotan
, Ashwin Narain
, Anne-Claire Jacomin
, Christina Schuelein-Voelk
, Carmina T. Fuss
, Nikolett Pahor
, Carsten Ade
, Viktoria Buck
, Michael Potente
, Vivian Li
, Gerti Beliu
, Armin Wiegering

T.N. Grossmann, Martin Eilers, Elmar Wolf, Hans Michael Maric, Mathias T. Rosenfeldt, Madelon Maurice, Ivan Dikic, Peter Gallant, Amir Orian (Oryan), Markus E. Diefenbacher

Research output: Contribution to Journal › Article › Academic › peer-review

Abstract

The contribution of deubiquitylating enzymes (DUBs) to β-Catenin stabilization in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, and by using an unbiassed screen, we discovered that the DUB USP10 stabilizes β-Catenin specifically in APC-truncated CRC in vitro and in vivo. Mechanistic studies, including in vitro binding together with computational modelling, revealed that USP10 binding to β-Catenin is mediated via the unstructured N-terminus of USP10 and is outcompeted by intact APC, favouring β-catenin degradation. However, in APC-truncated cancer cells USP10 binds to β-catenin, increasing its stability which is critical for maintaining an undifferentiated tumour identity. Elimination of USP10 reduces the expression of WNT and stem cell signatures and induces the expression of differentiation genes. Remarkably, silencing of USP10 in murine and patient-derived CRC organoids established that it is essential for NOTUM signalling and the APC super competitor-phenotype, reducing tumorigenic properties of APC-truncated CRC. These findings are clinically relevant as patient-derived organoids are highly dependent on USP10, and abundance of USP10 correlates with poorer prognosis of CRC patients. Our findings reveal, therefore, a role for USP10 in CRC cell identity, stemness, and tumorigenic growth by stabilising β-Catenin, leading to aberrant WNT signalling and degradation resistant tumours. Thus, USP10 emerges as a unique therapeutic target.

Original language	English
Article number	22
Pages (from-to)	3645-3659
Number of pages	15
Journal	Oncogene
Volume	43
Issue number	50
Early online date	23 Oct 2024
DOIs	https://doi.org/10.1038/s41388-024-03141-x
Publication status	Published - 2024

Funding

MR is funded by the DKH MSNZ Wuerzburg, DFG-GRK 2243 and IZKF B335. OH is supported by the German Cancer Aid via grant 70112491 and 70114554. ME is supported by the TransOnc priority programme of the German Cancer Aid within grant 70112951 (ENABLE). AO and MED are funded by the German Israeli Foundation grant 1431 1431 and ICRF project grant to AO. AO, ID and MED are funded by the DIP-DFG grant DIP DI 931/18-1. ID and MED are funded by the DFG-TRR 387. Open Access funding enabled and organized by Projekt DEAL. HMM and CS are funded by the DFG (DFG MA6957/1-1). The Operetta High Content Microscope was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) -440766788 (INST 93/1023-1 -FUGG).

Funders	Funder number
DFG-TRR
Israel Cancer Research Fund
Deutsche Forschungsgemeinschaft	DFG MA6957/1-1, INST 93/1023-1 -FUGG
German-Israeli Foundation for Scientific Research and Development	1431 1431
DIP-DFG	DIP DI 931/18-1
Deutsche Krebshilfe	70112491, 70114554, 70112951

Access to Document

10.1038/s41388-024-03141-x

Persistent URL (handle)

Persistent link

Cite this

Reissland, M., Hartmann, O., Tauch, S., Bugter, J., Prieto-Garcia, C., Schulte, C., Loebbert, S., Solvie, D., Bitman-Lotan, E., Narain, A., Jacomin, A.-C., Schuelein-Voelk, C., Fuss, C. T., Pahor, N., Ade, C., Buck, V., Potente, M., Li, V., Beliu, G., ... Diefenbacher, M. E. (2024). USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer. Oncogene, 43(50), 3645-3659. Article 22. https://doi.org/10.1038/s41388-024-03141-x

@article{27dc82d06db244f38ec1b8e3e3df8efc,

title = "USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer",

abstract = "The contribution of deubiquitylating enzymes (DUBs) to β-Catenin stabilization in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, and by using an unbiassed screen, we discovered that the DUB USP10 stabilizes β-Catenin specifically in APC-truncated CRC in vitro and in vivo. Mechanistic studies, including in vitro binding together with computational modelling, revealed that USP10 binding to β-Catenin is mediated via the unstructured N-terminus of USP10 and is outcompeted by intact APC, favouring β-catenin degradation. However, in APC-truncated cancer cells USP10 binds to β-catenin, increasing its stability which is critical for maintaining an undifferentiated tumour identity. Elimination of USP10 reduces the expression of WNT and stem cell signatures and induces the expression of differentiation genes. Remarkably, silencing of USP10 in murine and patient-derived CRC organoids established that it is essential for NOTUM signalling and the APC super competitor-phenotype, reducing tumorigenic properties of APC-truncated CRC. These findings are clinically relevant as patient-derived organoids are highly dependent on USP10, and abundance of USP10 correlates with poorer prognosis of CRC patients. Our findings reveal, therefore, a role for USP10 in CRC cell identity, stemness, and tumorigenic growth by stabilising β-Catenin, leading to aberrant WNT signalling and degradation resistant tumours. Thus, USP10 emerges as a unique therapeutic target.",

author = "Michaela Reissland and Oliver Hartmann and Saskia Tauch and Jeroen Bugter and Cristian Prieto-Garcia and Clemens Schulte and Sinah Loebbert and Daniel Solvie and Eliya Bitman-Lotan and Ashwin Narain and Anne-Claire Jacomin and Christina Schuelein-Voelk and Fuss, \{Carmina T.\} and Nikolett Pahor and Carsten Ade and Viktoria Buck and Michael Potente and Vivian Li and Gerti Beliu and Armin Wiegering and T.N. Grossmann and Martin Eilers and Elmar Wolf and Maric, \{Hans Michael\} and Rosenfeldt, \{Mathias T.\} and Madelon Maurice and Ivan Dikic and Peter Gallant and (Oryan), \{Amir Orian\} and Diefenbacher, \{Markus E.\}",

year = "2024",

doi = "10.1038/s41388-024-03141-x",

language = "English",

volume = "43",

pages = "3645--3659",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Springer Nature",

number = "50",

}

Reissland, M, Hartmann, O, Tauch, S, Bugter, J, Prieto-Garcia, C, Schulte, C, Loebbert, S, Solvie, D, Bitman-Lotan, E, Narain, A, Jacomin, A-C, Schuelein-Voelk, C, Fuss, CT, Pahor, N, Ade, C, Buck, V, Potente, M, Li, V, Beliu, G, Wiegering, A, Grossmann, TN, Eilers, M, Wolf, E, Maric, HM, Rosenfeldt, MT, Maurice, M, Dikic, I, Gallant, P, (Oryan), AO & Diefenbacher, ME 2024, 'USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer', Oncogene, vol. 43, no. 50, 22, pp. 3645-3659. https://doi.org/10.1038/s41388-024-03141-x

TY - JOUR

T1 - USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer

AU - Reissland, Michaela

AU - Hartmann, Oliver

AU - Tauch, Saskia

AU - Bugter, Jeroen

AU - Prieto-Garcia, Cristian

AU - Schulte, Clemens

AU - Loebbert, Sinah

AU - Solvie, Daniel

AU - Bitman-Lotan, Eliya

AU - Narain, Ashwin

AU - Jacomin, Anne-Claire

AU - Schuelein-Voelk, Christina

AU - Fuss, Carmina T.

AU - Pahor, Nikolett

AU - Ade, Carsten

AU - Buck, Viktoria

AU - Potente, Michael

AU - Li, Vivian

AU - Beliu, Gerti

AU - Wiegering, Armin

AU - Grossmann, T.N.

AU - Eilers, Martin

AU - Wolf, Elmar

AU - Maric, Hans Michael

AU - Rosenfeldt, Mathias T.

AU - Maurice, Madelon

AU - Dikic, Ivan

AU - Gallant, Peter

AU - (Oryan), Amir Orian

AU - Diefenbacher, Markus E.

PY - 2024

Y1 - 2024

N2 - The contribution of deubiquitylating enzymes (DUBs) to β-Catenin stabilization in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, and by using an unbiassed screen, we discovered that the DUB USP10 stabilizes β-Catenin specifically in APC-truncated CRC in vitro and in vivo. Mechanistic studies, including in vitro binding together with computational modelling, revealed that USP10 binding to β-Catenin is mediated via the unstructured N-terminus of USP10 and is outcompeted by intact APC, favouring β-catenin degradation. However, in APC-truncated cancer cells USP10 binds to β-catenin, increasing its stability which is critical for maintaining an undifferentiated tumour identity. Elimination of USP10 reduces the expression of WNT and stem cell signatures and induces the expression of differentiation genes. Remarkably, silencing of USP10 in murine and patient-derived CRC organoids established that it is essential for NOTUM signalling and the APC super competitor-phenotype, reducing tumorigenic properties of APC-truncated CRC. These findings are clinically relevant as patient-derived organoids are highly dependent on USP10, and abundance of USP10 correlates with poorer prognosis of CRC patients. Our findings reveal, therefore, a role for USP10 in CRC cell identity, stemness, and tumorigenic growth by stabilising β-Catenin, leading to aberrant WNT signalling and degradation resistant tumours. Thus, USP10 emerges as a unique therapeutic target.

AB - The contribution of deubiquitylating enzymes (DUBs) to β-Catenin stabilization in intestinal stem cells and colorectal cancer (CRC) is poorly understood. Here, and by using an unbiassed screen, we discovered that the DUB USP10 stabilizes β-Catenin specifically in APC-truncated CRC in vitro and in vivo. Mechanistic studies, including in vitro binding together with computational modelling, revealed that USP10 binding to β-Catenin is mediated via the unstructured N-terminus of USP10 and is outcompeted by intact APC, favouring β-catenin degradation. However, in APC-truncated cancer cells USP10 binds to β-catenin, increasing its stability which is critical for maintaining an undifferentiated tumour identity. Elimination of USP10 reduces the expression of WNT and stem cell signatures and induces the expression of differentiation genes. Remarkably, silencing of USP10 in murine and patient-derived CRC organoids established that it is essential for NOTUM signalling and the APC super competitor-phenotype, reducing tumorigenic properties of APC-truncated CRC. These findings are clinically relevant as patient-derived organoids are highly dependent on USP10, and abundance of USP10 correlates with poorer prognosis of CRC patients. Our findings reveal, therefore, a role for USP10 in CRC cell identity, stemness, and tumorigenic growth by stabilising β-Catenin, leading to aberrant WNT signalling and degradation resistant tumours. Thus, USP10 emerges as a unique therapeutic target.

UR - https://www.scopus.com/pages/publications/85206985985

UR - https://www.scopus.com/pages/publications/85206985985#tab=citedBy

U2 - 10.1038/s41388-024-03141-x

DO - 10.1038/s41388-024-03141-x

M3 - Article

SN - 0950-9232

VL - 43

SP - 3645

EP - 3659

JO - Oncogene

JF - Oncogene

IS - 50

M1 - 22

ER -

USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer

Abstract

Funding

Access to Document

Persistent URL (handle)

Other files and links

Fingerprint

Correction: USP10 drives cancer stemness and enables super-competitor signalling in colorectal cancer

Cite this